Edgar Filing: LA JOLLA PHARMACEUTICAL CO

Ownership Submission

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0104

Expires:

January 31, 2005

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

Â CARVER JENNIFER

2. Date of Event Requiring Statement (Month/Day/Year)
01/01/2016

3. Issuer Name and Ticker or Trading Symbol
LA JOLLA PHARMACEUTICAL CO [LJPC]

(Last)

(First)

(Middle)

C/O LA JOLLA PHARMACEUTICAL COMPANY,,Â 10182 TELESIS COURT, 6TH FLOOR

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

_____ Director	_____ 10% Owner
__X__ Officer (give title below)	_____ Other (specify below)
Sr. Vice President, Operations

5. If Amendment, Date Original Filed(Month/Day/Year)

(Street)

SAN DIEGO,Â CAÂ 92121

6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	2,500	D	Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	Â ⁽¹⁾	02/07/2024	Common Stock	18,000	$ 7.26	D	Â
Stock Option (Right to Buy)	Â ⁽²⁾	05/22/2024	Common Stock	10,000	$ 7.69	D	Â
Stock Option (Right to Buy)	Â ⁽³⁾	01/09/2025	Common Stock	12,000	$ 19.8	D	Â
Stock Option (Right to Buy)	Â ⁽⁴⁾	02/23/2025	Common Stock	23,500	$ 19.69	D	Â
Stock Option (Right to Buy)	Â ⁽⁵⁾	08/31/2025	Common Stock	20,000	$ 35.58	D	Â
Stock Option (Right to Buy)	Â ⁽⁶⁾	12/21/2025	Common Stock	51,000	$ 28.24	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
CARVER JENNIFER C/O LA JOLLA PHARMACEUTICAL COMPANY, 10182 TELESIS COURT, 6TH FLOOR SAN DIEGO,Â CAÂ 92121	Â	Â	Â Sr. Vice President, Operations	Â

Signatures

/s/ Ryan Murr, as attorney-in-fact for Jennifer A. Carver		01/11/2016
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	This option represents a right to purchase a total of 18,000 shares of the Issuer's Common Stock one quarter of which shall be fully vested and exercisable on February 7, 2015, with the remaining 13,500 shares vesting quarterly thereafter over the next three years.
(2)	This option represents a right to purchase a total of 10,000 shares of the Issuer's Common Stock one quarter of which shall be fully vested and exercisable on May 22, 2015, with the remaining 7,500 shares vesting quarterly thereafter over the next three years.
(3)	This option represents a right to purchase a total of 12,000 shares of the Issuer's Common Stock one quarter of which shall be fully vested and exercisable on November 20, 2015, with the remaining 9,000 shares vesting monthly thereafter over the next three years.
(4)	This option represents a right to purchase a total of 23,500 shares of the Issuer's Common Stock one quarter of which shall be fully vested and exercisable on February 23, 2016, with the remaining 17,625 shares vesting monthly thereafter over the next three years.
(5)	Option vests and becomes exercisable upon the achievement of certain performance-related goals in 2016. The timing for the achievement of such goals determines the number of shares underlying the award.
(6)	This option represents a right to purchase a total of 51,000 shares of the Issuer's Common Stock one quarter of which shall be fully vested and exercisable on December 21, 2016, with the remaining 38,250 shares vesting quarterly thereafter over the next three years.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.